AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 3.2 |
Market Cap | 603.53M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.44 |
PE Ratio (ttm) | -7.24 |
Forward PE | n/a |
Analyst | Strong Buy |
Ask | 3.4 |
Volume | 593,896 |
Avg. Volume (20D) | 907,170 |
Open | 3.38 |
Previous Close | 3.35 |
Day's Range | 3.18 - 3.38 |
52-Week Range | 2.21 - 4.72 |
Beta | undefined |
About ABUS
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel ...
Analyst Forecast
According to 4 analyst ratings, the average rating for ABUS stock is "Strong Buy." The 12-month stock price forecast is $5, which is an increase of 56.99% from the latest price.
Next Earnings Release
Analysts project revenue of $2.21M, reflecting a 3.03% YoY growth and earnings per share of -0.12, making a 0.00% YoY.
2 months ago · seekingalpha.com
Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call TranscriptArbutus Biopharma Corporation (NASDAQ:ABUS ) Q3 2024 Results Conference Call November 6, 2024 8:45 AM ET Company Participants Lisa Caperelli - VP, Investor Relations Mike McElhaugh - Interim President...